Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) saw a significant growth in short interest in the month of March. As of March 13th, there was short interest totaling 214,479 shares, a growth of 184.8% from the February 26th total of 75,311 shares. Based on an average daily trading volume, of 6,222,165 shares, the days-to-cover ratio is presently 0.0 days. Currently, 13.1% of the company’s shares are short sold. Currently, 13.1% of the company’s shares are short sold. Based on an average daily trading volume, of 6,222,165 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Trading of Catheter Precision

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC acquired a new stake in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision as of its most recent SEC filing. Institutional investors own 20.34% of the company’s stock.

Catheter Precision Stock Down 2.8%

NYSEAMERICAN:VTAK traded down $0.03 during mid-day trading on Wednesday, hitting $1.17. 53,105 shares of the company’s stock were exchanged, compared to its average volume of 1,180,733. Catheter Precision has a fifty-two week low of $1.14 and a fifty-two week high of $15.68. The company has a quick ratio of 0.46, a current ratio of 0.46 and a debt-to-equity ratio of 0.20. The company has a 50 day simple moving average of $1.71 and a 200-day simple moving average of $2.09.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.